AJMC: insurers drop GLP‑1 coverage

AJMC reported in August 2024 that insurers were beginning to pull back coverage for GLP-1 drugs used for weight loss, adding to out-of-pocket costs for patients who had been using the medicines to maintain treatment. The article pointed to Blue Cross Blue Shield of Michigan’s decision to stop covering semaglutide, tirzepatide and liraglutide for certain commercial members starting January 1, 2025. It described the move as part of a broader affordability fight over anti-obesity drugs that can cost hundreds or thousands of dollars a month without coverage. More recent payer and employer reporting shows the pullback has widened into 2026. ### Which drugs are being cut from coverage? AJMC named semaglutide, tirzepatide and liraglutide as the main drugs affected in the Michigan change, using the brand names Wegovy, Zepbound and Saxenda. Blue Cross Blue Shield of Michigan said in a September 27, 2024 provider alert that beginning January 1, 2025, or on a group’s 2025 renewal date, it would no longer cover those GLP-1 drugs when used for weight loss in Blue Cross and Blue Care Network commercial plans. (ajmc.com) Definitive Healthcare reported in February 2026 that other payers had also dropped GLP-1 coverage for obesity treatment, including Harvard Pilgrim Health Care, Blue Cross Blue Shield of Michigan and North Carolina’s Medicaid program. The same report said Blue Cross Blue Shield of Massachusetts dropped obesity-treatment GLP-1 coverage at the start of 2026 for employers with fewer than 100 employees. (ajmc.com) ### Why are insurers pulling back now? Blue Cross Blue Shield of Michigan said in its public explanation that GLP-1 drugs were “incredibly expensive” and that long-term risks were still unknown. AJMC separately cited Bloomberg reporting that a Michigan insurer spokesperson pointed to the drugs’ “effectiveness, safety and cost” in making the decision. (definitivehc.com) Definitive Healthcare said U.S. list prices for GLP-1 drugs run from about $900 to $1,400 a month. Peterson-KFF Health System Tracker said 34% of non-elderly people with employer-sponsored insurance — about 36.2 million people — have a body mass index that would medically qualify them for a GLP-1 drug, a scale that employers said could have a meaningful long-term effect on benefit costs. (bcbsm.mibluedaily.com) ### How much does this change matter for patients? Blue Cross Blue Shield of Michigan’s move was expected to affect nearly 10,000 members taking the drugs, according to AJMC and Bloomberg. AJMC said uninsured semaglutide could cost as much as $1,350 a month. Peterson-KFF said employers interviewed in 2025 reported that use was higher than expected and that covering the drugs significantly increased prescription spending. (definitivehc.com) Definitive Healthcare said ACA marketplace coverage for GLP-1s for weight loss fell from 3.6 million enrollees in 2024 to 2.8 million in 2026, with only 26 of 300 carriers offering coverage. (ajmc.com) ### What does this mean inside clinics? AJMC said patients losing coverage still had to meet their weight goals while facing higher direct costs. That creates a practical problem for clinicians: medication histories may no longer be stable if patients stop therapy, restart later, switch products or lose access between visits. That inference is supported by North Carolina Medicaid’s January 2026 reinstatement notice, which told prescribers to assess whether members had experienced a lapse in therapy, a treatment change or a need for a lower restarting dose. (healthsystemtracker.org) Blue Cross Blue Shield of Massachusetts said in 2025 that employers with more than 100 employees could choose to continue obesity-drug coverage, while standard exclusions would otherwise begin as plans renewed in 2026. That leaves the next step with employers, plan renewals and prescribers trying to determine whether patients will keep access to GLP-1 treatment under their specific benefit design. (bluecrossma.org) (ajmc.com)